MESO Jul 2024 12.000 call
| Previous close | 0.7500 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 1.1500 |
| Strike | 12.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.7500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireMesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U.S. Food and Drug Administration (FDA) next week. About Mesoblast Mesoblast (the Company) is a world leader in developi
Simply Wall St.ASX Growth Companies With High Insider Ownership To Watch In June 2024
As the ASX200 shows signs of a positive shift, buoyed by favorable movements in international markets and anticipation around the RBA's interest rate decision, investors are keenly watching for opportunities. In this environment, growth companies with high insider ownership on the ASX stand out as potentially strong candidates due to their aligned interests between management and shareholders.
- Simply Wall St.
Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120%
Amidst a mixed performance in the Australian market, with sectors like IT and Energy facing downturns while Telecommunications showed resilience, investors continue to navigate through a landscape marked by fluctuating commodity prices and economic data. In such an environment, growth companies with high insider ownership can offer unique investment opportunities as these insiders often have a vested interest in the company's success, aligning their goals closely with those of shareholders.
